The Clinical Core will enroll and follow study participants with genital HSV-2 as well as genital HSV-1 .
Specific Aims of the Clinical Core is 1) to recruit, screen and enroll into research protocols subjects fromdefined populations; 2) to follow participants prospectively on studies, maintaining close adherence to studyprocedures, and 3) to obtain clinical specimens required for virologic and immunologic laboratoryinvestigations detailed in Projects 1 and 3, using both standard and specialized techniques. In particular, theefforts will focus on enrolling a) participants with genital HSV-2 to address the specific aims of Project 1,including both HIV negative, HIV positive, pregnant women, and those with iatrogenic immunosuppression,and c) participants with genital HSV-2 to address the specific aims of Project 3. The core will also recruitand follow participants enrolled into studies examining the effect of antiviral therapy on HSV reactivation bothin HIV negative and HIV positive persons. For project 2, the Clinical Core will be a site where the neonateswho are receiving oral acyclovir will be evaluated and monitored.The Core is located at the University of Washington Virology Research Clinic (VRC). The VRC was foundedin 1974 as a center for studies of natural history and therapeutics of HSV infections. The clinic has followed>1000 persons with first episode of genital herpes and >3400 persons with recurrent HSV-2 infection. Theclinic has pioneered the use of daily genital swabs to evaluate the reactivation of HSV on mucosa, and tocharacterize the mucosal interactions between HSV and HIV. In the last decade, we have moved to usingHSV DNA PCR for evaluation of viral shedding; using this method, we have been able to demonstrate viralshedding in almost all HSV seropositive persons. Other procedures that have become standard in our clinicinclude biopsies of genital lesions and normal skin, rectal and cervical biopsies, UV light induction of genitalherpes recurrences, and leukapheresis for detailed virologic and immunologic studies of host-virusinteractions. Both host and viral DNA of participants in the detailed virologic and immunologic studies arestored for future investigations of genetic determinants of HSV susceptibility, resistance and disease severityas well as viral sequencing work.The Clinical Core is dedicated to recruiting, screening, enrolling and following persons who have HSVinfections into a variety of studies. Most persons are followed over time, often with daily swabs to measurethe frequency of viral shedding on the skin and mucosa. In addition, a variety of specialized techniques areavailable.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
2P01AI030731-18
Application #
7513500
Study Section
Special Emphasis Panel (ZAI1-MMT-M (M1))
Project Start
2008-07-15
Project End
2013-06-30
Budget Start
2008-07-15
Budget End
2009-06-30
Support Year
18
Fiscal Year
2008
Total Cost
$149,215
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Schiffer, Joshua T; Swan, Dave A; Roychoudhury, Pavitra et al. (2018) A Fixed Spatial Structure of CD8+ T Cells in Tissue during Chronic HSV-2 Infection. J Immunol 201:1522-1535
Traidl, Stephan; Kienlin, Petra; Begemann, Gabriele et al. (2018) Patients with atopic dermatitis and history of eczema herpeticum elicit herpes simplex virus-specific type 2 immune responses. J Allergy Clin Immunol 141:1144-1147.e5
Ramchandani, Meena; Selke, Stacy; Magaret, Amalia et al. (2018) Prospective cohort study showing persistent HSV-2 shedding in women with genital herpes 2 years after acquisition. Sex Transm Infect 94:568-570
Boucoiran, Isabelle; Mayer, Bryan T; Krantz, Elizabeth M et al. (2018) Nonprimary Maternal Cytomegalovirus Infection After Viral Shedding in Infants. Pediatr Infect Dis J 37:627-631
Kleinstein, Sarah E; Shea, Patrick R; Allen, Andrew S et al. (2018) Genome-wide association study (GWAS) of human host factors influencing viral severity of herpes simplex virus type 2 (HSV-2). Genes Immun :
Gilbert, Peter B; Excler, Jean-Louis; Tomaras, Georgia D et al. (2017) Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS One 12:e0176428
Celum, Connie; Hong, Ting; Cent, Anne et al. (2017) Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. J Infect Dis 215:907-910
Abana, Chike O; Pilkinton, Mark A; Gaudieri, Silvana et al. (2017) Cytomegalovirus (CMV) Epitope-Specific CD4+ T Cells Are Inflated in HIV+ CMV+ Subjects. J Immunol 199:3187-3201
Johnston, Christine; Magaret, Amalia; Roychoudhury, Pavitra et al. (2017) Highly conserved intragenic HSV-2 sequences: Results from next-generation sequencing of HSV-2 UL and US regions from genital swabs collected from 3 continents. Virology 510:90-98
Agyemang, Elfriede; Le, Quynh-An; Warren, Terri et al. (2017) Performance of Commercial Enzyme-Linked Immunoassays for Diagnosis of Herpes Simplex Virus-1 and Herpes Simplex Virus-2 Infection in a Clinical Setting. Sex Transm Dis 44:763-767

Showing the most recent 10 out of 345 publications